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On March 13, 2012 PLoS Medicine
published an analysis by Lisa Cosgrove
and Sheldon Krimsky [1] that examined
the financial conflicts of interest of mem-
bers of the American Psychiatric Associa-
tion (APA) responsible for updating the
Diagnostic and Statistical Manual of
Mental Disorders (DSM), the so-called
bible of psychiatry. Despite a new APA
policy designed to address conflicts of
interest (COIs), nearly 70% of current
DSM-5 task force members have financial
relationships with pharmaceutical compa-
nies, up from 57% for the manual’s
previous version. 83% of current contrib-
utors to the psychotic disorders section,
and everyone responsible for the sleep
disorder section, have links to the phar-
maceutical industry. Wide media coverage
and commentary about these findings [2–
5] have raised concerns that so many of
the experts charged with the responsibility
of defining mental health conditions and
treatments have financial ties to the very
companies that sell drug treatments for
mental health. It is widely established that
financial conflicts of interest impair objec-
tivity and integrity in medicine.
Concerns about the conflicts of interests
associated with the APA—undeniably the
leading authority for psychiatry and men-
tal health—are critical, not least because
of the association’s legacy of involvement
with the pharmaceutical industry: the
psychiatric profession receives more mon-
ey than any other medical specialty [6]
and has recently been scandalized by cases
of ghostwriting and publication bias. Their
judgments define mental illness, thus
legitimizing some disorders and denying
others, and determine what warrants
treatment and how. The DSM is used by
insurance companies, hospitals, courts,
prisons, schools, researchers, regulators,
and government agencies to define who is
sick/abnormal and who is not. The
expansion of diagnostic categories and
new diagnoses (and thus markets) in every
DSM is said to be a virtual ‘‘bonanza for
the pharmaceutical industry’’ [9]. And on
the other side of the coin, the DSM is a
boon for the APA, which sold over a
million copies of the DSM-IV; 20% of
APA funding is said to now come from
pharmaceutical companies [8].
Cosgrove and Krimsky also identified
several worrying gaps in the APA’s new
COI policy (previous DSMs in 1952,
1968, and 1980 were not subject to COI
policies). While the policy limits the
amount panel members can receive from
drug companies annually to US$10,000
and of their company stock holdings to
US$50,000, these are still considerable
amounts. (Even small gifts invoke obliga-
tions to reciprocate [6]). Worse, the policy
does not consider unrestricted research
grants from pharmaceutical companies to
be problematic and does not require they
be disclosed. Participation in lucrative
speakers’ bureaus (networks of prominent
physicians designed to influence commu-
nities of prescribers and usually forbidden
in medical schools) is likewise permitted
under the APA’s policy, and the monies
received for participation are required
only to be reported as honoraria, thus
concealing their true genesis. The APA
has responded to the PLoS Medicine analysis
by saying that the DSM-5 development
process ‘‘is the most open and transparent
of any previous edition of the DSM’’ [2].
But are disclosure mandates simply a
band-aid on a unrelenting problem of
bias?
Disclosure is generally considered pref-
erable to nondisclosure, because it makes
explicit and transparent details that are
important to the interpretation, credibility,
and value of the information presented—
vital in the context of clinical decision-
making and patient care. But the overem-
phasis and reliance on disclosure policies is
exactly what leaves the real problem of the
conflict of interest unaddressed.
Disclosure has severe limits as a strategy
for mitigating bias. Cosgrove and Krimsky
mention three reasons: that disclosure
alone merely shifts ‘‘secret bias’’ to ‘‘open
bias’’; that it sometimes involves so much
information about ties to the industry, for
example, that the reader is blinded by the
sheer ‘‘signal to noise ratio’’; and that
disclosure may be perceived as absolving a
person from their responsibility for man-
aging their conflict [1].
Even more compelling is evidence emerg-
ing from the social sciences that suggests
disclosure to be not only ineffective but also
regressive. Decision scientist George Loe-
wenstein and colleagues have argued that
disclosure can actually lead doctors to give
biased advice, either through strategic exag-
geration (whereby more biased advice is
provided to counteract anticipated discount-
ing), or ‘‘moral licensing’’ such that advice is
legitimized because advisees ‘‘have been
warned’’ (that is, caveat emptor or ‘‘buyer
beware’’) [7]. Their experiments have essen-
tially shown that bias is considerably greater
when conflicts of interest are disclosed.
Worse, because Loewenstein and colleagues
have demonstrated that advisees (i.e., pa-
tients) both think that their advisers (i.e.,
doctors) would never intentionally mislead
them and tend not to discount advice in light
of conflicts, disclosure policies will never be
the solution and are very likely exacerbating
the problem of bias in medicine [7].
Extending this analysis to the APA’s
DSM, the result would be disastrous if the
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concernsabout financial conflictsof interest
in deference to the authority of the APA.
And if clinical experts were to believe that
disclosure alone made them impervious to
bias, their advice forming the DSM may be
even more favorable toward the pharma-
cological products and markets their indus-
try funders seek and uphold.
Indeed, if disclosure worsens bias, then
this is a game-changer for discussion and
debate about managing conflicts of inter-
est in medicine. Journals, professional
associations, clinical guideline developers,
and others need to worry not just that
disclosure provides a band-aid to the real
problem of the COI itself, but that any
attempt to stem the trouble through
disclosure policies may actually be wors-
ening the problem.
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